HBM Healthcare Posts CHF 19 Million Profit Amidst Difficulties

HBM Healthcare Investments AG announced a profit of CHF 19 million for the 2024/2025 financial year, despite encountering challenging market conditions. The company's net asset value per share increased by 1.5%, although the share price experienced a slight decline of 2.6%. Key contributors to this growth were private companies, which overshadowed the negative performance in public company shares.

Private investments like Yellow Jersey Therapeutics and Dren Bio played significant roles, with the latter generating CHF 58 million following a deal with Sanofi. Conversely, the public company portfolio incurred impairments, notably Y-mAbs Therapeutics and Biohaven. Despite this, HBM's diversified strategy remains robust, balancing public and private equity interests.

The Board of Directors proposed an unchanged cash distribution of CHF 7.50 per share, reflecting a yield of 4.1%. HBM continues its share buy-back initiative, contributing to its strategy of securing balanced growth and returns.